
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. has demonstrated robust growth metrics, particularly in the design and implementation of the Organ Care System (OCS), with donor-derived cardiac (DCD) heart transplants increasing by 15% year-over-year and DCD livers by 44% during the current quarter-to-date analysis. The company has successfully captured substantial market share within the transplant arena, benefiting from notable increases in DCD transplant volume, which has contributed to a 7% growth in the overall heart, liver, and lung market. Additionally, upcoming product launches, enhanced adoption rates for lung transplants, and anticipated improvements in operating margins present significant potential for revenue growth, supporting positive projections for future revenue performance.
Bears say
TransMedics Group Inc. has experienced a decline in donor brain death (DBD) organs, with a 6% year-over-year and 13% month-over-month drop for livers, alongside a 6% year-over-year and 12% month-over-month decrease for hearts, which raises concern about the company's market position. Although there was a year-over-year growth in donor circulatory death (DCD) organs for livers and hearts, the overall trends show total DBD organ volumes have decreased by 2% quarter-over-quarter, suggesting potential challenges in sustaining growth. Furthermore, factors such as increasing competition, disappointing adoption rates for their Organ Care System, and possible reimbursement changes add to the negative outlook for TransMedics Group's future performance.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares